department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Alunbrig · pharmadog

pharmadog
drugs
Alunbrig

drug

patient view →

brigatinib

Marketedupdated 2mo ago

by Takeda Pharmaceuticals USA Inc

Approved

community read0 votes

indications

investigational

NSCLC

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Alunbrig

generic

brigatinib

indication

Non-Small Cell Lung Cancer

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

May 22, 2027

319 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

Nov 10, 2035compositionUS 10385078
Nov 10, 2035compositionUS 10385078
Nov 10, 2035compositionUS 10385078
Apr 10, 2034method-of-use (U-2837)US 9611283
Apr 10, 2034method-of-use (U-2837)US 9611283
Apr 10, 2034method-of-use (U-2837)US 9611283
Apr 28, 2031compositionUS 90124624.8y
Apr 28, 2031compositionUS 90124624.8y
Apr 28, 2031compositionUS 90124624.8y
May 21, 2029method-of-use (U-2837)US 92730772.9y
May 21, 2029method-of-use (U-2837)US 92730772.9y
May 21, 2029method-of-use (U-2837)US 92730772.9y

FDA exclusivities (3)

May 22, 2027ODE-300Orphan Drug (7y)319d
May 22, 2027ODE-300Orphan Drug (7y)319d
May 22, 2027ODE-300Orphan Drug (7y)319d

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 31m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying brigatinib

—Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancerrecruitingn=500
phase2Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotypingactive not recruitingn=118
—A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)active not recruitingn=154
phase2Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)active not recruitingn=100
phase2Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumorsrecruitingn=65
phase3A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancercompletedn=248
phase2A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinibcompletedn=103
—A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.completedn=5,279

more trials →